1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsConcept to Clinic: Commercializing Innovation (C3i) Program is sponsored by NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB). Provides medical device innovators with specialized business frameworks and tools for translating biomedical technologies from the lab to the market.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Concept to Clinic: Commercializing Innovation (C3i) Program | National Institute of Biomedical Imaging and Bioengineering Concept to Clinic: Commercializing Innovation (C3i) Program Director, Office of Program Evaluation and Strategic Partnerships The C3i Program is designed to provide innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic).
Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need.
The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their product. Overview: The eC3i course is an online entrepreneurial education platform aimed at teaching academic innovators methods to assess the commercial value of their biomedical technologies.
Eligibility: Investigators from a small business or research institution with active NIH-funded research projects Application Due Date: April 17, 2026 Notice of Participation: May 1, 2026 Program Start Date: June 1, 2026 Program End Date: August 21, 2026 C3i Validation / Execution Overview: The C3i Program is an in-depth, entrepreneurial training experience designed to help biomedical innovators validate a market need and viable business opportunity, as well as develop a compelling pitch for prospective investors and partners.
Eligibility: Investigators from a research institution or small business with active NIH-funded research projects Application Due Date: July 31, 2026 Notice of Participation: August 19, 2026 Program Start Date: September 28, 2026 Program End Date: April 29, 2027 Overview: The C3i Accell program provides product development and business support to assist academic innovators in accelerating the translation of their biomedical technologies.
Eligibility: Investigators from a research institution with active NIH-funded research projects who have completed the C3i Program. Please contact NIBIB-SBIR@mail. nih.
gov for additional details. The C3i Program is designed to provide innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic).
Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need.
The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their product. The C3i Program is based on the Coulter Commercialization Process, an approach to biomedical research translation developed and continuously refined by the Wallace H.
Coulter Foundation in collaboration with its academic partners across the country. Since 2001, the Foundation has supported more than 700 interdisciplinary teams of scientists and engineers, to bring the latest biomedical innovations to market for the benefit of human health and society at-large. To date 186 projects have raised more than $5.
3 billion in venture capital and more than 500 Thousand in SBIR funding, 61 projects has been licensed to industry partners, and dozens more have received SBIR support. Most importantly, these efforts have given risen to more than 52 products with more than 50 advancing through the various FDA pathways.
The key features and elements which define the Coulter Commercialization Process have been captured and condensed into an intensive, fast-paced training course, the C3i Program. In 2014, the NIBIB and the Coulter Foundation established a public-private partnership to offer the C3i curriculum to NIH-supported investigators.
Over the past ten years, C3i courses have provided mentored business training to over 220 participating teams and 540 individuals. Cumulatively, these teams have received over $120M in SBIR/STTR grant funding and have raised over $600M in private capital investment, and over 40 products have been commercially launched on the market.
According to the current listing, eligibility includes: Small businesses in the U. S. with fewer than 500 employees. Confirm the full requirements in the official notice before applying.
The current listing shows up to $400,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Concept to Clinic: Commercializing Innovation (C3i) Program is funded by NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The NIH Common Fund launched PRIMED-AI — Precision Medicine with AI: Integrating Imaging with Multimodal Data — as five coordinated funding opportunities (RFA-RM-27-011 through -015) that build a full pipeline from standards to clinic. Here is how the Playbook, Data-to-Model partnerships, Model-to-Clinic translation, Validation Center, and Logistics Center fit together, what each pays, who is eligible, and how to position before the October 2026 deadlines.
Read articleThe April 14 SBIR/STTR reauthorization restarted NIH's small-business pipeline after the shutdown, but the real signal is the sequencing of the new Small Business 101 webinars: program overview June 9, budget July 14, foreign risk August 18.
Read articleNIH's accelerating use of multiyear-funded grants — 601 awards worth $402 million in the first half of FY26, against just 146 awards worth $75 million in the same window of FY24 — has produced a fiscal contraction at research universities that has begun cascading into PhD admissions. AAU member institutions are admitting smaller graduate cohorts than they did in 2024 or 2025, with downstream consequences for the biomedical workforce, lab continuity, and the foreign-student pipeline through 2030. Why the contraction is structural rather than cyclical, and what universities, PIs, and prospective trainees should be doing in the second half of 2026.
Read article